We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Hepatic encephalopathy
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Hepatic encephalopathy (HE) is a nervous system-related mental disorder for which symptoms include level of consciousness, slowing down of thoughts and movements, deterioration of mental status, confusion, and, in severe forms, coma. HE is a common complication of chronic liver cirrhosis caused by abnormal levels of toxins that accumulate in the blood, which are normally excreted in a healthy liver. We are carrying out a clinical study to understand the effect of a drug called rifaximin in treating patients with HE and how rifaximin is used in the management of HE in routine UK clinical practice.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2017 Results article in http://fg.bmj.com/content/early/2017/04/07/flgastro-2016-100792 results
You can take part if:
You may not be able to take part if:
1. Patients receiving rifaximin where subsequent clinical diagnosis excludes hepatic encephalopathy 2. Patients initiated on rifaximin at hospitals not taking part in the study3. Patients for whom hospital records are unavailable
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Mark
Hudson
+44(0)191 233 6161
Mark.Hudson@nuth.nhs.uk
The study is sponsored by Norgine Ltd (UK) and funded by Norgine Ltd (UK).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
